- Home
- NVGS vs NVCR Comparison
NVGS vs NVCR Comparison
Compare NVGS & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVGS | NVCR |
|---|---|---|
| Founded | 1997 | 2000 |
| Country | United Kingdom | Switzerland |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2013 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NVGS | NVCR |
|---|---|---|
| Price | $20.65 | $12.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $21.50 | ★ $28.08 |
| AVG Volume (30 Days) | 406.3K | ★ 1.1M |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | N/A | $7.72 |
| Revenue Next Year | N/A | $6.74 |
| P/E Ratio | $13.06 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $12.04 | $9.82 |
| 52 Week High | $21.36 | $20.05 |
Technical Indicators
Market Signals| Indicator | NVGS | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 60.51 | 60.84 |
| Support Level | $17.38 | $12.66 |
| Resistance Level | $21.36 | $13.34 |
| Average True Range (ATR) | 0.59 | 0.54 |
| MACD | 0.09 | 0.29 |
| Stochastic Oscillator | 91.42 | 84.84 |
Price Performance
Historical ComparisonAbout NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). The company plays a vital role in the globalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users, and commodity traders.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.